In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni by Neves, Bruno J et al.
In Silico Repositioning-Chemogenomics Strategy
Identifies New Drugs with Potential Activity against
Multiple Life Stages of Schistosoma mansoni
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Abstract
Morbidity and mortality caused by schistosomiasis are serious public health problems in developing countries. Because
praziquantel is the only drug in therapeutic use, the risk of drug resistance is a concern. In the search for new
schistosomicidal drugs, we performed a target-based chemogenomics screen of a dataset of 2,114 proteins to identify drugs
that are approved for clinical use in humans that may be active against multiple life stages of Schistosoma mansoni. Each of
these proteins was treated as a potential drug target, and its amino acid sequence was used to interrogate three databases:
Therapeutic Target Database (TTD), DrugBank and STITCH. Predicted drug-target interactions were refined using a
combination of approaches, including pairwise alignment, conservation state of functional regions and chemical space
analysis. To validate our strategy, several drugs previously shown to be active against Schistosoma species were correctly
predicted, such as clonazepam, auranofin, nifedipine, and artesunate. We were also able to identify 115 drugs that have not
yet been experimentally tested against schistosomes and that require further assessment. Some examples are aprindine,
gentamicin, clotrimazole, tetrabenazine, griseofulvin, and cinnarizine. In conclusion, we have developed a systematic and
focused computer-aided approach to propose approved drugs that may warrant testing and/or serve as lead compounds
for the design of new drugs against schistosomes.
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Introduction
Schistosomiasis is one of the main neglected tropical diseases
affecting humans. It is caused by flatworms of the genus
Schistosoma (S. mansoni, S. japonicum, S. haematobium, S.
intercalatum and S. mekongi) [1–3]. This parasitic disease ranks
second only after malaria in terms of its public health importance
[4] because of its chronic and debilitating characteristics that result
in a substantial burden on human health [5,6]. Recent estimates
suggest that more than 249 million people were infected in 78
endemic countries located in sub-Saharan Africa, the Middle East,
the Caribbean, and South America, resulting in 200,000 deaths
annually [7].
Schistosomes have complex life cycles that involve vertebrate
(often a mammal) and invertebrate (aquatic snail) hosts, in which
sexual and asexual reproductive phases occur, respectively.
Mammalian definitive hosts are infected via skin penetration by
cercariae, which lose their bifurcated tail and become schistosom-
ula [8,9]. After 5–7 days, schistosomula migrate from the lungs to
the hepatic portal system via the blood stream and transform into
adult worms. Male and female worms pair in the hepatic portal
system and migrate to the mesenteric veins (except S. haemato-
bium, which migrates to the urogenital system) to lay nearly 300
eggs per day. These eggs either pass into the gut lumen to be
voided in the faeces and continue the life cycle or pass through the
mesenteric veins and lodge in the liver, where they can cause
granulomatous changes and fibrosis, both of which are key
contributors to schistosomiasis [8,10].
In the absence of a vaccine, praziquantel (PZQ) has been the
drug of choice recommended by the World Health Organization
for the treatment and control of all the major Schistosoma species
in mass drug administration programs for almost three decades
[11]. More recently, the use of artemisinin derivatives alone or in
combination with PZQ for the treatment and prevention of
schistosomiasis has shown encouraging results [12], but it is
unlikely to represent an ideal stand-alone drug-based control
strategy. Moreover, the suboptimal efficacy of PZQ against
immature worms that are present in newly acquired infections
[13] and the prospect of drug resistance indicate a need to identify
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new schistosomicidal drugs active against multiple stages of
parasite life cycle [5,14–16].
One approach that can expedite drug discovery process is to
find new uses for existing approved compounds, a practice
commonly known as drug repositioning or repurposing [17]. Drug
repositioning has proved to be an efficient way of identifying new
therapies against neglected tropical diseases. A recent example of a
repositioned drug is miltefosine, a drug that was originally
developed to treat breast cancer and is now used against visceral
leishmaniasis [18,19]. In addition to saving money and time, an
advantage of drug repositioning is that the existing drugs have
already been scrutinized in terms of pharmacokinetic and toxicity
parameters [20–22].
Over the last few decades, advances in computer technologies
have resulted in useful tools to assist early drug discovery and
development. In this context, the use of in silico tools can reduce
the cost and the time required to select the most promising
candidates for in vitro and in vivo assays [20]. Our laboratory has
been developing and applying many computer-assisted drug
discovery (CADD) strategies in the hope of discovering new drug
candidates for neglected tropical diseases [23–43].
Several in silico chemogenomic studies have demonstrated that
genome-wide gene expression data might also represent a useful
resource for identifying drugs and drug target genes that can
potentially be used for drug repositioning [44–47]. The ultimate
goal of chemogenomics is to establish the molecular relationship(s)
between ligands and drug targets. Therefore, various publicly
available databases, such as Therapeutic Target Database (TTD)
[48], DrugBank [49], and STITCH [50], which integrate
information about gene/protein–drug–disease interactions, are
useful resources to develop these strategies. Based on the concept
that ‘‘similar targets have similar ligands’’, homology-based
searching using these databases helps to identify compounds that
may act on a target for which there are no known active
compounds but that are related by homology to one or more
targets for which active compounds are known [51,52]. In such
context, S. mansoni targets with structural homology similar to
known targets of approved drugs are more likely to be susceptible
to inhibitors listed in the drug target and drug databases.
Recently, Protasio et al. [53] used transcriptomic sequencing
from four time points in the S. mansoni life cycle to refine gene
predictions and establish expression profiles in the parasite.
Consequently, a high-resolution map of the temporal changes in
the transcription of genes was produced for all intra-mammalian
life cycle stages of S. mansoni. These data have been compiled into
a searchable format within the SchistoDB (www.schistodb.net) and
GeneDB (www.genedb.org) databases [53]. Transcription profil-
ing and genome sequencing data provide important fundamental
information to support further advances in schistosome research.
In the present study, we used an in silico target-based
chemogenomics strategy, integrating S. mansoni genomics data
with drug-target database resources to predict new drugs with
potential activity against multiple life stages of S. mansoni.
Materials and Methods
Compilation of the list of S. mansoni genes
The target-based chemogenomics screening was performed on a
dataset containing 2,076 genes that are differentially expressed
among the 24 hour schistosomula vs. adult life stages obtained
from Protasio et al. [53]. We also obtained 38 S. mansoni genes
from the TDR Targets database [54] using the target search tool.
We searched for targets with ‘‘any form of validation’’, which
included ‘‘genetic’’, ‘‘pharmacological’’, and ‘‘observed pheno-
types’’ (S1 Table). We focused on searching for genes that are
expressed in ‘‘24 h schistosomula vs. adult’’ because they are intra-
mammalian stages. However, some of these genes are also
expressed in other temporal life cycle stages, such as ‘‘cercariae
vs. 3 hour schistosomula’’ and ‘‘3 h vs. 24 h schistosomula’’.
These genes are considered promising targets for prophylactic
drugs because they are involved in the penetration through the
mammalian host’s skin, host adaptation, and differentiation and
growth of the parasite. Therefore, genes were grouped according
to the following division: group I was composed of genes
differentially transcribed between ‘‘24 h schistosomula vs. adult’’
and also between ‘‘cercariae and 3 h schistosomula’’; group II was
composed of genes differentially transcribed between ‘‘24 h
schistosomula vs. adults’’ as well as between ‘‘3 h and 24 h
schistosomula’’; group III was composed of genes transcribed
between ‘‘24 h schistosomula vs. adult’’; and group IV was
composed of genes transcribed concurrently in all the life cycle
stages (Fig. 1A). Information for individual genes or gene products
(primary amino acid sequence in FASTA format, target name, and
biological process/es) was then retrieved from the GeneDB S.
mansoni genome database [55]. We then verified the annotation of
each single putative protein and corrected it, if necessary,
according to the recent updated annotations in the GeneDB
database. For convenience, the in silico target-based chemoge-
nomic pipeline is presented in Fig. 2.
Identification of putative drug targets using publicly
available drug databases
Each predicted protein from S. mansoni was used to interrogate
three different publicly available databases that provide detailed
information on drugs and their targets: TTD [48], DrugBank [49],
and STITCH [50]. The search strategy for DrugBank and TTD
was based on the principle of homology, whereby each query (S.
mansoni target) was compared for matches to known drug targets
contained in each of these databases. In cases where homologous
drug targets were identified, all proteins with an output
expectation value (E-value) of #10220 for DrugBank and TTD
were listed as ‘‘acceptable targets’’. This E-value represents the
number of hits with an alignment score ‘‘Z’’ or equal or better
than ‘‘Z’’ that would be expected by chance when searching a
database. The E-value is the expected number of times a
Author Summary
Schistosomiasis is a neglected tropical disease caused by
schistosome parasites that affects millions of people
worldwide. The current reliance on a single drug (Prazi-
quantel) for treatment and control of the disease calls for
the urgent discovery of novel schistosomicidal agents. One
approach that can expedite drug discovery is to find new
uses for existing approved drugs, a practice known as drug
repositioning. Currently, modern drug repositioning strat-
egies entail the search for compounds that act on a
specific target, often a protein known or suspected to be
required for survival of the parasite. Drug repositioning
approaches for schistosomiasis are now greatly facilitated
by the availability of comprehensive schistosome genome
data in user-friendly databases. Here, we report a drug
repositioning computational strategy that involves identi-
fication of novel schistosomicidal drug candidates using
similarity between schistosome proteins and known drug
targets. Researchers can now use the list of predicted
drugs as a basis for deciding which potential schistosomi-
cidal candidates can be tested experimentally.
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homology match will occur at random in a given set of trials.
However, the STITCH database integrates data from the
literature and various databases of biological pathways, drug–
target relationships, and binding affinities. The resultant network
can be explored interactively or used as the basis for a confidence
score ranging from 0–1. The confidence score is a set of high-
confidence interactions between drugs and targets (i.e., proteins
with shared Gene Ontology annotations) that is used as a reference
for screening results. Therefore, in the case of the STITCH
database, when significant matches were found, only targets with a
score $0.8 were considered [50]. We filtered all predicted targets
through inclusion in the list of only those proteins that were
indicated to interact with approved drugs, excluding the
nutraceutical class, as these compounds are unlikely to exhibit
schistosomicidal activity [56].
Pairwise alignment and comparison of functional regions
Predicted S. mansoni targets were aligned with their homologue
drug targets using pairwise BLAST [57]. We considered the S.
mansoni targets for further evaluation only in cases where there
was $80% overlap with the corresponding drug target. This
filtering step enhances the probability of both proteins sharing the
same active site. Subsequently, we performed the sequence
alignment and compared the functional regions among the
approved drug targets and S. mansoni targets using the ConSurf
server [58]. This procedure was used to estimate the conservation
of active sites between the proteins and the preservation of affinity
for the predicted schistosomicidal drugs. The ConSurf server [58]
is a bioinformatic tool for estimating the evolutionary conservation
of amino acid positions in a protein based on the phylogenetic
relationships between homologous sequences. Therefore, the
degree of conservation of the amino acids within the active site
of each approved drug target was estimated using 150 homologues
from other organisms with similar sequences in the UniProt
database [59]. The sequences were clustered and those presenting
high sequence similarity (.95%) were excluded using the
algorithm CD-HIT [60] to filter out redundant sequences. In
the same way, the sequences that shared less than the given
identity cutoff of ,35% were also ignored [58]. A multiple
sequence alignment (MSA) of the homologous sequences was
constructed using the MAFFT-L-INS-I method [61], and the
phylogenetic tree was built using the neighbor-joining algorithm
[62]. Position-specific conservation scores were computed using
the empirical Bayesian method [63]. Next, the functional regions
of each approved drug target were visually compared with the
corresponding S. mansoni target. The results were classified as
functional residues with high ($80%) or moderate conservation
(60–79%). In cases where the conservation between functional
residues was less than 59%, the putative targets were excluded
from further analyses.
List of drugs yet to be tested against Schistosoma species
We carried out a literature search using the PubMed, PubChem
Bioassay database, and SciFinder engines to identify approved
drugs that have not been evaluated against Schistosoma species by
querying all predicted drugs previously identified. The PubChem
BioAssay database reports the available biological screening results
for the chemical compounds described in the PubChem database,
providing searchable descriptions of each bioassay, including
descriptions of the conditions and readouts specific to that
screening procedure. SciFinder is a chemistry research application
that provides access to the world’s most comprehensive and
authoritative sources of references, chemical substances, and
reactions in chemistry and is updated daily by Chemical Abstracts
Service. Our definition of ‘‘evaluation’’ embraces biochemical or
in vitro and in vivo assessments of one or more life stages of
Fig. 1. Distribution of genes from S. mansoni and predicted targets. (A) Venn diagram represents the clustering of genes in four different
groups according to temporal life stages of the parasite. (B) Rate of druggable S. mansoni targets identified for each group using the target-based
chemogenomics approach.
doi:10.1371/journal.pntd.0003435.g001
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Schistosoma species. Therefore, if a given drug is noted as ‘‘not
tested’’, it means that no publication record was found after either
of the following search details: 1. (‘‘drug name’’ [MeSH Terms]
OR ‘‘drug name’’ [All Fields]) AND (‘‘Schistosoma’’ [MeSH
Terms] OR ‘‘Schistosoma’’ [All Fields]) and 2. (‘‘drug name’’
[MeSH Terms] OR ‘‘drug name’’ [All Fields]) AND (‘‘schistoso-
miasis’’ [MeSH Terms] OR ‘‘schistosomiasis’’ [All Fields]). It also
might mean that the studies/assays retrieved were insufficiently
informative to infer the potential usefulness of the drug as a
schistosomicidal drug or lead compound.
Chemical space analysis
We evaluated the ‘‘chemical space’’ of known active and
inactive compounds against Schistosoma. The aim in using this
strategy is to find whether predicted compounds share essential
structural and physicochemical properties with schistosomicidal
compounds. Initially, a dataset of active compounds with
enzymatic, in vitro, and/or in vivo activity data for Schistosoma
species was collected from the literature (S2 Table) using the
PubMed and PubChem Bioassay databases [64]. Because of the
differences in the experiments used for the biological activity
evaluation, compounds of our database were considered to be
active according to the specifications of each study or bioassay. In
addition, a dataset of inactive compounds was compiled from a
large dataset of non-inhibitors of the enzyme thioredoxin
glutathione reductase of S. mansoni previously reported (Pub-
Chem Bioassay AID: 485364). These compounds were assumed to
be inactive, because in the literature they were not reported to
produce any schistosomicidal activity. All aforementioned chem-
ical datasets were carefully curated and standardized according to
the protocol proposed by Fourches et al. [65]. Structural
normalization of specific chemotypes, such as aromatic and nitro
groups, was performed using ChemAxon Standardizer (v.6.1.3,
ChemAxon, Budapest, Hungary, http://www.chemaxon.com).
Duplicates (i.e., identical compounds reported several times in
the dataset) were identified using KSAR workflow (http://labmol.
farmacia.ufg.br/ksar). The dataset is unbalanced, meaning that
the size of the active and inactive classes does not match.
Therefore, we used the algorithm k-Nearest Neighbor (kNN)
developed in software R and the qsaR 1.5 package (http://labmol.
farmacia.ufg.br/chemoinformatics) to equalize the number of
compounds in different classes; this is referred to as ‘‘dataset
balancing’’. The basic principle here is to evaluate the whole active
dataset represented by the MACCS fingerprint matrix evaluating
Fig. 2. Flowchart summarizing the in silico repositioning chemogenomics strategy and corresponding results. The green boxes
represent the summarized results obtained at each stage of the study.
doi:10.1371/journal.pntd.0003435.g002
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Fig. 3. ConSurf analysis of the functional regions between an approved drug target and the corresponding S. mansoni target. (A)
ConSurf predictions demonstrated on human proteasome b type 2 (Gene ID: PSMB2), using 150 homologues obtained from the UNIPROT database.
The sequence of the query protein is displayed with the residue conservation scores at each site color-coded onto it. The color-coding bar shows the
coloring scheme; conserved amino acids are colored bordeaux, residues of average conservation are white, and variable amino acids are turquoise.
The residues of the query sequence are numbered starting from 1 to 199. The first row below the sequence lists the predicted burial status of the site
(i.e. ‘‘b’’– buried versus ‘‘e’’ – exposed). The second row indicates residues predicted to be structurally and functionally important: ‘‘s’’ and ‘‘f’’,
respectively. (B) Analysis of the functional regions conserved with the corresponding S. mansoni proteasome b type 2. The green rectangles represent
the conserved functional residues and red rectangles represent non-conserved functional residues.
doi:10.1371/journal.pntd.0003435.g003
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the Euclidean distance to the MACCS fingerprint of each inactive
compound. The compounds were reordered by nearest k-distance
of the active compounds. Thereafter, a set representing 39
descriptors accounting for physicochemical properties were
calculated using RDKit 2.4.0 [66]. The descriptor matrix was
normalized, and low variance descriptors (variance upper bound
set to 0.0) were removed before generating the model. The
chemical space analysis of predicted drugs was generated using k-
means clustering space using Principal Component Analysis (PCA)
and employing the software R v.3.0.3 [67]. All steps of dataset
balancing, processing, and chemical space analysis were imple-
mented in R and KNIME, a graphical user interface that allows
the assembly of nodes for modeling, data analysis, and visualiza-
tion (S1 Fig.).
Results
Compilation of the genes list
The dataset of S. mansoni genes was compiled from the Protasio
et al. study and the TDR Targets database, totalling 2,114 genes
(S1 Table). We focused on searching drugs with potential activity
in schistosomula and adult life cycle stages, which are all intra-
mammalian stages. For this reason, genes that do not have a
differential transcription between 24 h schistosomula and adults
were not considered. Some of the genes differentially transcribed
between these stages were also transcribed in other life cycle
stages, including the cercariae; therefore, some of these genes are
considered promising targets for drugs, as they are expected to be
involved in penetration through mammalian host skin, adaptation,
differentiation, and growth. The 2,114 genes were clustered in
four main groups (I–IV) according to transcription in each life
cycle stage (Fig. 1A). Totals of 478, 328, 1,134, and 174
transcribed genes were identified.
Identification of putative drug targets using publicly
available drug databases
The information about individual genes (primary amino acid
sequence in FASTA format, target name, and biological process)
was retrieved from the GeneDB S. mansoni genome database.
Based on the FASTA sequence information, we predicted
schistosomicidal drugs using the sequence similarity screening in
three databases (DrugBank, STITCH 3.1, and TTD). In this step,
numerical statistical probability parameters (E-value #10220 or a
score $0.8) were adopted to provide high confidence for the data.
We decided to use all three databases because each of them may
contain different drug-target datasets and, consequently, the
probability of targets and their drugs being missed is reduced.
This analysis predicted 49 targets associated with 276 approved
drugs (S3 Table).
Pairwise alignment and comparison of functional regions
Pairwise sequence alignment was used to compare the S.
mansoni targets previously identified with their approved homol-
ogous drug targets using BLAST alignment. Ten targets had less
than an 80% overlap with their corresponding approved targets
and were excluded from further analyses due to the improbability
of both proteins sharing the same active site. Next, we performed
sequence alignments and comparisons of functional regions for
approved drug targets and predicted S. mansoni targets. This step
allowed the identification of functionally relevant features and
conserved residues necessary for catalysis and residues critical for
binding. Fig. 3 shows an example of the ConSurf analysis of the
functional regions between an approved drug target (human
proteasome b type 2) and the corresponding S. mansoni target.
Fig. 3A shows the predictions demonstrated on human protea-
some b type 2 (Gene ID: PSMB2) using 150 homologues obtained
from the UniProt database. This analysis revealed that 38 residues
were predicted to be functionally important to the catalytic activity
of the human enzyme. The functional regions of the human
proteasome b type 2 were aligned to the respective S. mansoni
orthologue. This comparison demonstrated that the active site
predicted for S. mansoni proteasome b type 2 is conserved when
compared to functional regions of its respective human target
(Fig. 3B).
Compilation of the ‘‘predicted targets list’’
After running each of the S. mansoni protein sequences through
the three databases, all proteins with negative results (negative hits)
were excluded from further analyses, whilst predicted targets from
each database were compiled into a single Excel file, hereafter
called the ‘‘predicted targets list’’ (S3 Table). Each positive hit was
examined further using BLAST pairwise alignment and the
ConSurf server. This strategy resulted in a list of 39 potential
druggable S. mansoni targets (,1.8% of the interrogated targets)
that could interact with 215 approved drugs. The DrugBank,
STICH 3.1 and TTD databases exclusively predicted 120 (56.0%),
6 (2.8%), and 18 (8.3%) of the approved drugs, respectively, whilst
the remaining 71(32.9%) drugs were predicted by two or three of
these databases. Detailed information about the predicted targets
and their associated drugs are provided in S3 Table. The
distribution of the 39 identified S. mansoni targets according to
their expression group is shown in Fig. 1B. We found that 19
(48.7%) of the predicted S. mansoni targets are in group III, 7
(17.9%) are in group I, 6 (15.4%) are in group II, and 7 (17.9%)
are in group IV (Fig. 1B and S3 Table).
List of drugs yet to be tested against Schistosoma species
To investigate which of the predicted drugs have already been
tested against Schistosoma species, we undertook a literature search
of PubMed, PubChem Bioassay, and SciFinder. A total of 22
druggable targets associated with 47 drugs whose activity has been
previously evaluated against Schistosoma were identified. Exam-
ples of some of these drugs and their corresponding targets are
given in Table 1. Accordingly, we were confident that our
chemogenomic strategy for identifying new schistosomicidal drugs
is valid. Consequently, we predicted 168 drugs to be active against
33 druggable targets that have not yet been experimentally tested
against schistosomes or that have not yet required further studies.
The results are summarized in Fig. 2. The complete list of
predicted drugs, their targets, alignment parameters, and conser-
vation of the functional regions is given in S3 Table.
Chemical space analysis
Finally, we used chemical space analysis to map the 168
predicted drugs in a multidimensional space using physicochem-
ical descriptors for a dataset of active and inactive compounds
against Schistosoma reported in the literature. The chemical space
analysis is useful to refine the results and select the most promising
drugs that share essential structural and physicochemical proper-
ties with schistosomicidal compounds. Because the original dataset
was unbalanced, containing 355 active compounds vs. 331,228
inactive compounds (extracted from 101 bibliographic references,
including 87 articles from PubMed and 14 from PubChem
bioassays), it was not appropriate to build multivariate models
[33]. For this reason, a balanced dataset containing 696 chemical
structures (355 active compounds vs. 341 inactive compounds, S2
Table) was generated using the kNN method.
In Silico Repositioning Chemogenomics for New Schistosomicidal Drugs
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The chemical space mapping was performed using k-means
clustering via PCA using 39 physicochemical descriptors (Fig. 4).
According to the PCA, the first and second principal components
(PCs) explained 70.9% of the total variability of data and were
categorized into five main clusters. Most of the compounds
predicted to be active were located in regions marked in purple
and green at the upper right corner of the score plot, totaling 215
active compounds (91.8%) and 19 inactive compounds (8.2%)
(Fig. 4, clusters 3 and 5, respectively). Moreover, the inactive
compounds were mostly delimited into the blue region containing
291 inactive compounds (74.4%) and 100 active compounds
(25.6%) (Fig. 4, cluster 4). The red regions located in the center
and at the upper right corner were flagged as inconclusive, as they
contained similar proportions of both classes of compounds (Fig. 4,
clusters 1 and 2, respectively). Remarkably, 115 drugs predicted by
the proposed methodology are inside the overlapping area of the
chemical space of the active compounds (Fig. 4, clusters 3 and 5)
and are more likely to be active, whereas only 53 drugs were inside
the overlapping area of the inactive compounds and the
inconclusive clusters (Fig. 4, clusters 4, 1 and 2). Therefore, a
‘‘repurposing drug’’ located in the cluster regions 3 and 5 has a
high probability (92%) of being active.
Discussion
The main goal of this study was to identify drugs approved for
clinical use in humans that may have potential schistosomicidal
activity by performing a search of publicly available drug/target
databases. However, since most target databases are only starting
to be established, the predicted S. mansoni targets are not yet
scored for druggability. The druggability concept adds a structural
dimension and evaluates the likelihood that small drug-like
molecules can bind a given target with sufficient potency to alter
its activity [68–70]. Druggability is related to many factors,
including the size of targets, the presence of pockets, and the
overall charge and hydrophobicity of the interaction surface [68].
A number of factors were considered in this study in order to
provide both confidence for the data generated and a solid basis
from which to predict the druggability of individual S. mansoni
targets. The predicted S. mansoni targets were considered
druggable if they presented a sequence overlap $80%, a score
$0.8, or an E-value #10220 in relation to their predicted
homologous targets and the high or moderate conservation of the
functional regions. The overlapping sequences and analysis of
functional regions among approved drug targets and S. mansoni
targets revealed the importance of each position for the function of
the predicted protein and the possible preservation of affinity for
the predicted drug. Following this precondition, we were able to
identify 168 drugs with the potential to inhibit their targets known
to be transcribed in multiple life stages of S. mansoni. Moreover, in
validation of the proposed chemogenomic strategy, several drugs
previously demonstrated to be active against Schistosoma species in
experimental assays were predicted by our methodology (Table 1
and S3 Table). Consequently, we were confident that our strategy
for predicting schistosomicidal drugs is useful.
Additionally, we also evaluated the structural and physico-
chemical properties of known active and inactive schistosomicidal
compounds to map the chemical space that is accessed by the 168
predicted drugs using the chemogenomics strategy. Chemical
space is a term that is commonly used in place of ‘‘multi-
dimensional descriptor space’’, which is a region defined by a
particular choice of descriptors encompassing all the possible
compounds that could be mapped to the coordinates of this multi-
dimensional space [71,72]. This concept is closely related to the
notion of chemical diversity. The diversity of a chemical library is
a quantitative description of how different these compounds are
from each other, with similar compounds and similar biological
activities falling in the same chemical space region [73]. For this,
we used k-means clustering via PCA, a method to compute the
position of every compound in a two-dimensional coordinate
system based on a set of computed properties. The PCA reduces
high-dimensional data into a lower-dimensional space, thus
making it more manageable and comprehensible by extracting
essential information [74,75]. Indeed, PCA transforms the
original measured variables, such as physicochemical descriptors,
into new uncorrelated variables called PCs, which are a linear
combination of the original measured variables. As a result, we
found that 115 drugs predicted by this chemogenomics strategy
are inside the chemical space of active schistosomicidal
compounds, yielding a higher degree of confidence in the
predictions.
Table 1. Examples of approved drugs and their potential S. mansoni targets that were previously reported on the literature,
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79.5% of reduction of adult
worms 25 days after
infection (100 mg/kg) [110]
clonazepam hypnotic and sedative peripheral type benzodiazepine
receptor (Smp_102510.1)
receptor activity high conservation
(83%)
IC50 = 10 mM in adult worms
[111]
auranofin antirheumatic thioredoxin glutathione
reductase (Smp_048430.1)
cell redox homeostasis high conservation
(92%)
IC50 = 0.7 nM enzymatic
assay [112]
artesunate antimalarial Ca2+ transporting ATPase
(Smp_136710.1)
Ca2+ homeostasis high conservation
(99%)
97.1% reduction of adult
worms 30 days after
infection (30 mg/kg) [113]
nifedipine antihypertensive voltage-dependent calcium
channel (Smp_159990.1)
Ca2+ homeostasis high conservation
(88%)
Loss of motility and muscle
contraction in adult worms
(1 mg/kg) [82]
doi:10.1371/journal.pntd.0003435.t001
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A previous chemogenomics screen in S. mansoni described by
Caffrey et al. [47] identified 35 potential druggable targets for
further investigation in drug discovery programs, showing the
value of in silico approaches for drug discovery for schistosomiasis.
Interestingly, only one drug target identified in that study
(methionine aminopeptidase: Target ID = Smp_011120.1) is
present amongst our predicted targets, which is likely because the
studies differ significantly in their methodology. In addition,
Berriman et al. [53] also reported an in silico approach to predict
schistosomicidal drugs using the StARlite database and conserva-
tive parameters (#50% sequential identity and $80% overlap) for
target exclusion. Only eight predicted drugs identified in our study
(carbidopa, colchicine, dasatinib, deserpine, mycophenolate mo-
fetil, mycophenolic acid, reserpine and ribavirin) are overlapping
in both studies. This small number might relate to the different
gene datasets, different databases, and different parameters for
conservation filtering used [76].
One of our goals was to predict targets that control the muscle
function and motility of the parasite. Schistosomes depend on their
muscular systems for motility, penetration of host skin (cercariae),
and migration (schistosomules). Additionally, schistosomes use
their muscular system for pairing and mating and reproductive,
digestive, and excretory processes. These responses are essential
for the survival of the parasite. These behaviors require precise
coordination not only of the musculature that enables the
movement but also of the responses regulated by the neurotrans-
mitters needed for successful motility [77]. Drugs that disrupt one
or more of these motility functions would be expected to interfere
with the normal life of the parasite and would consequently cause
its death. It is noteworthy that PZQ, the drug of choice to treat
schistosomiasis, disrupts the muscle function and causes paralysis
of the worm [78]. Currently, the gold standard test for measuring
drug activity for S. mansoni is the in vitro assessment of worm
motility, measured visually through microscopy [79]. Further-
more, we suggest that 61 drugs have potential activity against the
muscle function and motility of the parasite because they were
predicted to interact with 4 neurotransmitter transporters
(nicotinic acetylcholine receptor a subunit, Target ID =
Smp_031680.1; Na+/Cl- dependent transporter, Target ID
= Smp_193800.1; vesicular amine transporter, Target ID =
Smp_121920.1; and Na+/Cl- dependent neurotransmitter trans-
porter, and Target ID = Smp_160360.1); 2 ion channels (Ca2+
transporting ATPase, Target ID = Smp_136710.1 and voltage-
dependent Ca2+ channel, Target ID = Smp_159990.1); and 2
indirectly related proteins (calmodulin, Target ID =
Smp_026560.2; and acetylcholinesterase, Target ID =
Smp_154600.1) (S3 Table). These drugs are attractive when
related to the study reported by Smout et al. [79] that can simply
and objectively assess anthelmintic activity by measuring parasite
motility in real time in a fully automated high-throughput
screening.
Another important aspect considered in this study has to do
with intellectual property protection of the potential schistosomi-
cidal drugs predicted by the proposed strategy, particularly for
those drugs that are off-patents. Pre-existing patents could impede
the commercialization of schistosomicidal repositioned drugs and
make them uneconomical, given that schistosomiasis predomi-
nantly affects poor populations in low- and middle-income
countries. Therefore, an extensive search was done to collect the
patent information (expiration date) of the predicted drugs using
the European Patent Office database, Google Patents, and
SciFinder. We found that 80.9% of the predicted drugs are off-
patents (S3 Table). Last, we refer specifically to six drugs that we
suggest are candidates for pre-clinical (in vitro and in vivo) studies
Fig. 4. Chemical space analysis of the schistosomicidal compounds. Purple and green regions (clusters 3 and 5, respectively) represent the
chemical space of active compounds. 115 drugs predicted by our strategy are inside this area and are more likely to be active. The blue region
(cluster 4) represents the chemical space of inactive compounds and red region (clusters 1 and 2) are inconclusive spaces. 53 predicted drugs are
inside this area and are more likely to be inactive. The first and second components explain 70.9% of the total variability.
doi:10.1371/journal.pntd.0003435.g004
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(Table 2). The remaining drugs were not discussed in detail,
because we found that pharmacokinetic and toxicity properties
may render them less suitable as schistosomicidal drugs than the
above chemicals. For example, ixabepilone and pralatrexate are
antineoplastic drugs and thus might cause severe toxicity in
humans. However, we consider that all predicted drugs identified
in this study are attractive for further analysis.
Cinnarizine is an antagonist of the histamine H1 receptor used
for the control of nausea due to motion sickness. This drug is also
considered a potent dilator of peripheral vessels because of its
ability to block Ca2+ channels [80,81]. The present study suggests
that cinnarizine may also be able to inhibit the S. mansoni voltage-
dependent L-type calcium channel subunit alpha-1S (Target ID =
Smp_159990.1; E-value = 0; functional regions = 88% conserva-
tion), which is homologous to the human enzyme. Curiously, PZQ
is considered a Ca2+ channel activator, which would allow more
Ca2+ channels to open and lead to the disruption of normal
intracellular Ca2+ levels. After exposure to PZQ, diverse effects
become apparent in adult worms, such as muscular contraction
and tegumental disruption, which subsequently leads to the
exposure of parasite antigens on the worm’s surface [78]. Despite
the activator effect of PZQ on Ca2+ channels, a recent study
demonstrated that treatment with nifedipine, a Ca2+ channel
blocker, resulted in antischistosomal activity against schistosomula
and significantly reduced their viability. Adult worms were also
affected by nifedipine and exhibited impaired motility, several
lesions on the tegument, intense contractility, and the reduction of
egg deposition [82].
Griseofulvin is a fungistatic drug that is orally administered in
the treatment of cutaneous mycoses. It was originally biosynthe-
sized from Penicillium griseofulvum in 1939 [83], but its in vivo
efficacy was first demonstrated only in 1958. Results from the
present study suggest that griseofulvin might also be able to inhibit
the S. mansoni tubulin-b chain (Target ID = Smp_192110.1; E-
value = 0; score = 0.8; functional regions = 99% conservation),
which is homologous to the Candida albicans protein and is
expected to be involved in cytoskeleton formation. Griseofulvin is
able to inhibit the growth of fungal, plant, and mammalian cells by
blocking the cells at the G2/M phase of the cell cycle [84,85]. In
fungi, griseofulvin deteriorates spindle and cytoplasmic microtu-
bules, resulting in nuclear and mitotic abnormalities followed by
distortions in hyphal morphology. Microtubules form a highly
organized cellular cytoskeleton in eukaryotic cells, and their
aggregation–disaggregation plays a key role in cell morphology
and growth [86]. The concentration of griseofulvin required to
deteriorate the spindle and cytoplasmic microtubules of fungal
cells is much lower than that required to inhibit normal healthy
mammalian cells due to its higher affinity for fungal tubulin
as compared to mammalian tubulin [87–90]. Furthermore,
griseofulvin selectively induces apoptosis in several cancer cell
lines, sparing the normal healthy cells [85,91]. Therefore, we
consider that griseofulvin has low toxicity against normal healthy
cells, which makes it highly appropriate for clinical use.
Tetrabenazine is a reversible human vesicular monoamine
transporter type 2 inhibitor. It acts within the basal ganglia and
promotes the depletion of monoamine neurotransmitters, such as
serotonin and dopamine, in nerve terminals [92]. In this study, we
suggest that tetrabenazine might also be able to block the vesicular
amine transporter of S. mansoni (Target ID = Smp_121920.1; E-
value = 3.062130; functional regions = 73% conservation). S.
mansoni also has a sophisticated nervous system that includes both
central and peripheral elements and employs a wide range of
neurotransmitter transporters. Among them, there are vesicular
amine transporters that are normally responsible for the uptake of
cytosolic biogenic amines into synaptic vesicles. Serotonin and
dopamine are largely responsible for neuromuscular signaling in
the parasite, and therefore, the carriers are expected to be
important components of the worm’s motor control system
[77,93]. It is worth noting that amine transport inhibitors have
been shown to have strong effects on the parasite, as demonstrated
in two medium-throughput drug screens of S. mansoni [94,95].
Clotrimazole is an antifungal drug commonly used to treat yeast
infections of the vagina, mouth, and skin, such as athlete’s foot,
jock itch, and body ringworm. This drug is a potent inhibitor of
14-a demethylase, resulting in increased cellular permeability. It is
also capable of inhibiting the movement of Ca2+ and K+ ions
across the cell membrane by blocking the Ca2+-activated K+
channel [96]. The present study suggests that clotrimazole might
also be able to block the S. mansoni Ca2+-activated K+ channel
(Target ID = Smp_161450.1; E-value = 1.09248; functional
regions = 80% conservation). The Ca2+-activated K+ channel is
essential for maintaining the membrane in a hyperpolarized state,
thereby regulating neuronal excitability, smooth muscle contrac-
tion, and secretion [97,98]. Thus, the blocking of Ca2+-activated
K+ channels in the muscle membranes of S. mansoni could be
intimately involved in the dysfunction of rhythmic muscle activity.
Due to its own chemical nature, clotrimazole is not well absorbed
from the gastrointestinal tract. However, since clotrimazole is
commercially available in powder form, it may be tested directly
after dilution in an appropriate vehicle in experimental models of
schistosomiasis with administration via a route other than oral,
such as intra-peritoneal.
Gentamicin is an aminoglycoside drug composed of a mixture
of related gentamicin components and is used to treat many types
of bacterial infections, particularly those caused by gram-negative
organisms. This drug binds the 30S subunit to the 16S ribosomal
RNA (rRNA) of bacteria, but its affinity to the heat shock protein
(HSP) 73 has also been well established [99]. We found that
Table 2. Examples of potential schistosomicidal drugs and their potential targets revealed in this study.
Drug Therapeutic class S. mansoni target (Target ID) Biological process Functional regions (%)
cinnarizine anti-allergic voltage-dependent calcium channel
(Smp_159990.1)
Ca2+ homeostasis high conservation (88%)
griseofulvin antifungal tubulin b chain, putative (Smp_192110.1) cytoskeleton formation high conservation (99%)
tetrabenazine antipsychotic vesicular amine transporter (Smp_121920.1) neurotransmitter transport moderate conservation (73%)
clotrimazole antifungal Ca2+-activated K+ channel (Smp_161450.1) K+ homeostasis high conservation (80%)
gentamicin antibacterial heat shock protein 73 (Smp_106930.1) protein folding high conservation (98%)
aprindine antiarrhythmic calmodulin, putative (Smp_134500.1) Ca2+ binding messenger high conservation (100%)
doi:10.1371/journal.pntd.0003435.t002
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gentamicin might be able to interfere with the heat shock protein
70 of S. mansoni (Target ID = Smp_106930.1; E-value = 0;
functional regions = 98% conservation), a homologue of the
human HSP73. HSPs are a family of proteins involved in basic
life-protecting mechanisms against harmful extracellular effects,
primarily heat shock response. Normally, the expression of these
proteins is increased in response to cellular adaptation to high
temperatures [100]. Among the HSP family, HSP70 is considered
the most predominantly conserved with intracellular chaperone
and extracellular immunoregulatory functions [101]. In S.
mansoni, it is well established that HSP70 is involved in protein
re-folding and the chaperone function as an adaptive response to
the rapid temperature rise between fresh water (, 28uC), in which
the cercariae are found, and the warmer mammalian host
(, 37uC) [53].
Last, we refer to aprindine as a candidate. This is possibly one of
the least obvious drugs to hold schistosomicidal activity because it
is not an anti-infective agent but rather an anti-arrhythmic drug.
An interesting fact is that aprindine has a binding affinity to
calmodulin [102]. Thus, we suggest that aprindine may also be
able to inhibit the S. mansoni calmodulin (Target ID =
Smp_026560.2; E-value = 4.45281; functional regions = 100%
conservation). Calmodulin is the primary sensor of intracellular
Ca2+ levels that binds to and regulates a number of diverse target
proteins involved in different functions, such as muscle contrac-
tion, apoptosis, and the immune response [103]. In S. mansoni,
selective calmodulin inhibitors are known to disrupt egg hatching
or cause miracidia to become vesiculated and die without
undergoing transformation to the sporocyst stage [104,105].
Ca2+ mobilization also plays a role in the cercarial penetration
processes, possibly by calcium regulation of protease activities
during infection [106,107]. It is important to mention that Ca2+
ions are second messengers that are crucial for many biological
functions, including muscle contraction, metabolism, and cell
motility [108]. Importantly, visual inspection of the chemical
structures allowed us to discover that aprindine is chemically
similar (two aromatic centers and one aliphatic amine) to tricyclic
drugs, a chemical class of the psychoactive drugs overactive against
schistosomula stages [94].
Besides the drugs highlighted above, 109 other drugs are
predicted to be active against S. mansoni. In all cases, we
considered the numerical parameters (overlap, conserved func-
tional regions, E-value, and score) for target homology sufficiently
significant to infer drug predictions. Moreover, we verified that
these drugs are ‘‘inside the chemical space’’ of active schistoso-
micidal compounds, making the predictions more reliable.
Therefore, all 115 predicted drugs are candidates for drug
repositioning and might be used as starting points for further in
vitro and in vivo studies and schistosomicidal drug design because
they are privileged structures and have established pharma-
cokinetic and toxicity profiles considered suitable for lead
optimization.
Conclusions
We used an in silico drug repositioning strategy based on the
concept that ‘‘similar targets have similar ligands’’ to compile a list
of drugs with potential activity against schistosomes. In doing so,
we predicted 115 such compounds that we suggest justify
evaluation as schistosomicidal drugs. We recognize that the
activity of such compounds might be affected by appropriate
chemical affinity with their predicted target. However, in addition
to previous strategies, we used the criterion of conservation of
functional residues among S. mansoni and its homologous targets
and investigated the chemical space of known schistosomicidal
compounds to further increase confidence in our predictions.
Primary in vitro screens with these drugs might provide insights
into their schistosomicidal activity. If promising activities are
discovered, they could constitute important starting points for lead
identification and optimization.
Supporting Information
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